RESEARCH
Research Focus
Our research is centered on pioneering innovative technologies for the precise delivery of drugs and biologics to targeted tissues. A key area of interest is the development of implantable devices that house engineered therapeutic cells, capable of autonomously sensing and treating diseases without the need for external intervention. By integrating cutting-edge advances in genomic engineering, molecular sciences, biomaterials, electronics, and multi-scale fabrication techniques, we aim to create transformative solutions that redefine therapeutic approaches and enhance patient outcomes.
Immune-instructive biomaterials
The foreign body reaction to biomaterials presents a significant challenge to the long-term function of implanted devices. Our research focuses on unraveling the complex immune interactions between implanted devices and the host tissue. We aim to develop innovative strategies to mitigate the rejection responses. By designing new immune-instructive materials and grafts, we strive to enhance the integration of implanted devices with the host tissue, ensuring better compatibility and long-term success.
Bioelectronic Cell Implants
We are developing advanced implantable devices that seamlessly integrate biological and electronic components. These bioelectronic cell implants are designed to interact with the host environment and remotely monitor and modulate the device's function in real time. By combining the precision of electronics with the complexity of biological systems, we aim to create smart implants that can autonomously adapt to the body's needs, potentially revolutionizing the way we approach long-term treatments and chronic conditions.
Advanced Testing Platform for Cell Therapy
Engineered cells, such as CAR-T and CAR-Treg cells, hold the promise of delivering long-term cures for cancers and autoimmune diseases. While animal models have been the gold standard in preclinical studies, they often fall short in replicating the complexity of human physiology and patient diversity. To address this gap, we are developing a cutting-edge testing platform using patient-derived tissues in our lab. This platform is designed to mimic the entire journey of engineered cells—from circulation to their targeted disease sites—providing a more accurate, human-relevant assessment of cell therapy effectiveness.
